keyword
https://read.qxmd.com/read/38497942/the-edmonton-symptom-assessment-system-is-a-valid-reliable-and-responsive-tool-to-assess-symptom-burden-in-decompensated-cirrhosis
#1
JOURNAL ARTICLE
John Donlan, Chengbo Zeng, Teresa Indriolo, Lucinda Li, Enya Zhu, Joyce Zhou, Kedie Pintro, Nora Horick, Maria Edelen, Raymond T Chung, Areej El-Jawahri, Nneka N Ufere
BACKGROUND: While there is a growing need for interventions addressing symptom burden in patients with decompensated cirrhosis (DC), the lack of validated symptom assessment tools is a critical barrier. We investigated the psychometric properties of the revised Edmonton Symptom Assessment System (ESAS-r) in a longitudinal cohort of patients with DC. METHODS: Adult outpatients with DC were prospectively recruited from a liver transplant center and completed ESAS-r at baseline and week 12...
April 1, 2024: Hepatology Communications
https://read.qxmd.com/read/38495286/contemporary-concepts-of-prevention-and-management-of-gastroesophageal-variceal-bleeding-in-liver-cirrhosis-patients
#2
EDITORIAL
Dmitry Victorovich Garbuzenko
This editorial describes the contemporary concepts of prevention and management of gastroesophageal variceal bleeding in liver cirrhosis (LC) patients according to the current guidelines. Gastroesophageal variceal bleeding is the most dangerous complication of portal hypertension in LC patients. Risk stratification and determination of an individual approach to the choice of therapeutic measures aimed at their prevention and management has emerged as one of the top concerns in modern hepatology. According to the current guidelines, in the absence of clinically significant portal hypertension, etiological and non-etiological therapies of LC is advisable for the primary preventing gastroesophageal variceal bleeding, whereas its presence serves as an indication for the administration of non-selective β-blockers, among which carvedilol is the drug of choice...
February 27, 2024: World Journal of Hepatology
https://read.qxmd.com/read/38495281/can-rifaximin-for-hepatic-encephalopathy-be-discontinued-during-broad-spectrum-antibiotic-treatment
#3
EDITORIAL
Chien-Hao Huang, Piero Amodio
Hepatic encephalopathy (HE) is a formidable complication in patients with decompensated cirrhosis, often necessitating the administration of rifaximin (RFX) for effective management. RFX, is a gut-restricted, poorly-absorbable oral rifamycin derived antibiotic that can be used in addition to lactulose for the secondary prophylaxis of HE. It has shown notable reductions in infection, hospital readmission, duration of hospital stay, and mortality. However, limited data exist about the concurrent use of RFX with broad-spectrum antibiotics, because the patients are typically excluded from studies assessing RFX efficacy in HE...
February 27, 2024: World Journal of Hepatology
https://read.qxmd.com/read/38487923/the-challenges-and-potential-of-microrna-based-therapy-for-patients-with-liver-failure-syndromes-and-hepatocellular-carcinoma
#4
REVIEW
Oliver D Tavabie, Siamak Salehi, Varuna R Aluvihare
INTRODUCTION: Morbidity and mortality from liver disease continues to rise worldwide. There are currently limited curative treatments for patients with liver failure syndromes, encompassing acute liver failure and decompensated cirrhosis states, outside of transplantation. Whilst there have been improvements in therapeutic options for patients with hepatocellular carcinoma (HCC), there remain challenges necessitating novel therapeutic agents. microRNA have long been seen as potential therapeutic targets but there has been limited clinical translation...
March 15, 2024: Expert Opinion on Therapeutic Targets
https://read.qxmd.com/read/38487559/regional-variations-in-inpatient-decompensated-cirrhosis-mortality-may-be-associated-with-access-to-specialist-care-results-from-a-multicentre-retrospective-study
#5
JOURNAL ARTICLE
(no author information available yet)
INTRODUCTION: Specialist centres have been developed to deliver high-quality Hepatology care. However, there is geographical inequity in accessing these centres in the United Kingdom (UK). We aimed to assess the impact of these centres on decompensated cirrhosis patient outcomes and understand which patients transfer to specialist centres. METHODS: A UK multicentred retrospective observational study was performed including emergency admissions for patients with decompensated cirrhosis in November 2019...
January 2024: Frontline Gastroenterology
https://read.qxmd.com/read/38486819/infections-increase-the-risk-of-decompensation-and-death-in-patients-with-early-alcohol-related-liver-disease
#6
JOURNAL ARTICLE
Stine Johansen, Simon Langkjær, Ditlev Nytoft Rasmussen, Mads Israelsen, Nikolaj Torp, Katrine Lindvig, Maria Kjærgaard, Johanne Kragh Hansen, Camilla Dalby Hansen, Katrine Thorhauge, Peter Andersen, Sönke Detlefsen, Helene Bæk Juel, Ulrik Stenz Justesen, Torben Hansen, Aleksander Krag, Maja Thiele
BACKGROUND & AIMS: Infections are frequent in patients with cirrhosis and worsen prognosis. We evaluated the incidence of infections and their impact on decompensation and death in patients with early alcohol-related liver disease (ALD) during long-term follow-up. METHODS: We performed a prospective cohort study of patients in secondary care with a history of excess alcohol intake, no prior decompensation, and with liver biopsies along with clinical investigations conducted at baseline...
April 2024: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/38486673/novel-nurse-led-early-postdischarge-clinic-is-associated-with-fewer-readmissions-and-lower-mortality-following-hospitalisation-with-decompensated-cirrhosis
#7
JOURNAL ARTICLE
Benjamin Giles, Kirsty Fancey, Karen Gamble, Zeshan Riaz, Joanna K Dowman, Andrew J Fowell, Richard J Aspinall
OBJECTIVE: Patients hospitalised with decompensated cirrhosis have high rates of early unplanned readmission. Many readmissions are avoidable with secondary preventative strategies, but patients are often readmitted prior to outpatient review. To address this, we established a novel, nurse-led early postdischarge (EPD) clinic delivering goal-directed care for cirrhosis complications and evaluated the impact. METHODS: Retrospective cohort study comparing outcomes in 78 patients seen in the EPD clinic with 91 phenotypically matched controls receiving standard, consultant hepatologist care...
March 2024: Frontline Gastroenterology
https://read.qxmd.com/read/38481634/corrigendum-to-trends-in-decompensated-cirrhosis-and-hepatocellular-carcinoma-among-people-with-a-hepatitis-b-notification-in-new-south-wales-jhep-reports-4-2022
#8
Syed Hassan Bin Usman Shah, Maryam Alavi, Behzad Hajarizadeh, Gail V Matthews, Marianne Martinello, Mark Danta, Janaki Amin, Matthew G Law, Jacob George, Heather Valerio, Gregory J Dore
[This corrects the article DOI: 10.1016/j.jhepr.2022.100552.].
March 2024: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/38479613/one-year-transplant-free-survival-following-hospital-discharge-after-icu-admission-for-aclf-in-the-netherlands
#9
JOURNAL ARTICLE
Jubi de Haan, Fabian Termorshuizen, Nicolette de Keizer, Diederik Gommers, Caroline den Hoed
BACKGROUND & AIMS: Patients with acute decompensated (AD) liver cirrhosis or acute-on-chronic liver failure (ACLF) often require intensive care unit (ICU) admission for organ support. Existing research, mostly from specialized liver transplant centers, largely addresses short-term outcomes. Our aim was to evaluate in-hospital mortality and 1-year transplant-free survival after hospital discharge in the Netherlands. METHODS: We conducted a nationwide observational cohort study, including patients with an history of cirrhosis or first complications of cirrhotic portal hypertension admitted to ICUs in the Netherlands between 2012 and 2020...
March 11, 2024: Journal of Hepatology
https://read.qxmd.com/read/38479612/validation-of-baveno-vii-criteria-and-other-non-invasive-diagnostic-algorithms-for-clinically-significant-portal-hypertension-in-hepatitis-delta
#10
JOURNAL ARTICLE
Mathias Jachs, Lisa Sandmann, Lukas Hartl, Tammo Tergast, Michael Schwarz, David Josef Maria Bauer, Lorenz Balcar, Alena Ehrenbauer, Benedikt Silvester Hofer, Markus Cornberg, Henrike Lenzen, Katja Deterding, Michael Trauner, Mattias Mandorfer, Heiner Wedemeyer, Thomas Reiberger, Benjamin Maasoumy
BACKGROUND AND AIMS: Non-invasive tests (NIT) for clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) lack validation in patients infected with hepatitis D virus (HDV). METHODS: HDV-cACLD patients (LSM ≥10 kPa or histological METAVIR F3/F4 fibrosis) who underwent paired HVPG and NIT assessment at Medical University of Vienna or Hannover Medical School between 2013 and 2023 were retrospectively included...
March 11, 2024: Journal of Hepatology
https://read.qxmd.com/read/38478755/safety-and-efficacy-of-off-label-bulevirtide-monotherapy-in-hdv-patients-with-decompensated-child-b-cirrhosis-a-real-world-case-series
#11
JOURNAL ARTICLE
Christopher Dietz-Fricke, Elisabetta Degasperi, Mathias Jachs, Benjamin Maasoumy, Florian P Reiter, Andreas Geier, Julia M Grottenthaler, Christoph P Berg, Kathrin Sprinzl, Stefan Zeuzem, Juliana Gödiker, Bernhard Schlevogt, Toni Herta, Johannes Wiegand, Roberta Soffredini, Heiner Wedemeyer, Katja Deterding, Thomas Reiberger, Pietro Lampertico
BACKGROUND AIMS: Chronic hepatitis D is the most debilitating form of viral hepatitis frequently progressing to cirrhosis and subsequent decompensation. However, the HDV entry inhibitor bulevirtide is only approved for antiviral treatment of patients with compensated disease. We aimed for the analysis of real-world data on the off-label use of bulevirtide in the setting of decompensated liver cirrhosis. APPROACH RESULTS: We conducted a retrospective study in HDV-patients with decompensated liver disease at German, Austrian and Italian centers...
March 13, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38478751/feasibility-of-hepatitis-c-elimination-by-screening-and-treatment-alone-in-high-income-countries
#12
JOURNAL ARTICLE
Feng Tian, Farinaz Forouzannia, Zeny Feng, Mia J Biondi, Andrew B Mendlowitz, Jordan J Feld, Beate Sander, William W L Wong
BACKGROUND AIMS: Despite the availability of highly effective direct-acting antiviral therapy, chronic hepatitis C (CHC) continues to cause a major public health burden. In many high-income countries, treatment rates have been declining, which was exacerbated by the impact of the COVID-19 pandemic, threatening the ability to meet the World Health Organization (WHO)'s targets for eliminating hepatitis C virus (HCV) as a public health threat by 2030. We sought to model the impact of CHC in Canada, a resource-rich country with ongoing immigration from HCV-endemic regions; which relies exclusively on risk-based screening for case identification...
March 13, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38477839/clinical-outcomes-with-metformin-use-in-diabetic-patients-with-compensated-cirrhosis-a-systematic-review-and-meta-analysis
#13
JOURNAL ARTICLE
Spyros Peppas, Stavros Doumas, Advait Suvarnakar, Jiling Chou, Ayah Arafat, Akram I Ahmad, James H Lewis
BACKGROUND: Previous studies have demonstrated a beneficial effect of metformin in patients with cirrhosis, but no improvement in liver histology. AIM: To investigate the impact of metformin on mortality and hepatic decompensation in people with diabetes with compensated cirrhosis. METHODS: Medline, Embase and Cochrane databases were searched from inception to February 2023 for studies reporting results regarding the impact of metformin on all-cause mortality and hepatic decompensation in people with diabetes with compensated cirrhosis...
March 11, 2024: European Journal of Gastroenterology & Hepatology
https://read.qxmd.com/read/38474048/human-amniotic-msc-response-in-lps-stimulated-ascites-from-patients-with-cirrhosis-foxo1-gene-and-th17-activation-in-enhanced-antibacterial-activation
#14
JOURNAL ARTICLE
Mariangela Pampalone, Nicola Cuscino, Gioacchin Iannolo, Giandomenico Amico, Camillo Ricordi, Giampiero Vitale, Claudia Carcione, Salvatore Castelbuono, Simone Dario Scilabra, Claudia Coronnello, Salvatore Gruttadauria, Giada Pietrosi
Spontaneous bacterial peritonitis (SBP) is a severe complication in patients with decompensated liver cirrhosis and is commonly treated with broad spectrum antibiotics. However, the rise of antibiotic resistance requires alternative therapeutic strategies. As recently shown, human amnion-derived mesenchymal stem cells (hA-MSCs) are able, in vitro, to promote bacterial clearance and modulate the immune and inflammatory response in SBP. Our results highlight the upregulation of FOXO1, CXCL5, CXCL6, CCL20, and MAPK13 in hA-MSCs as well as the promotion of bacterial clearance, prompting a shift in the immune response toward a Th17 lymphocyte phenotype after 72 h treatment...
February 28, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38471790/health-related-quality-of-life-and-frailty-in-liver-cirrhosis
#15
JOURNAL ARTICLE
Yangyang Hui, Han Wang, Gaoyue Guo, Wanting Yang, Xiaoyu Wang, Binxin Cui, Xiaofei Fan, Chao Sun
BACKGROUND AND OBJECTIVES: There is limited evidence concerning the predictive value of health-related quality of life (HRQoL) on the presence of frailty in the context of cirrhosis. We aimed to elucidate the relationship between HRQoL and multidimensional frailty and to determine which HRQoL dimension independently impacted frail phenotype in our established cohort. METHODS: This was a prospective observational study by consecutively enrolling 355 patients with cirrhotic with decompensated signs in China...
March 12, 2024: BMJ Supportive & Palliative Care
https://read.qxmd.com/read/38466796/inhibition-of-sodium-glucose-cotransporter-2-and-liver-related-complications-in-individuals-with-diabetes-a-mendelian-randomization-and-population-based-cohort-study
#16
JOURNAL ARTICLE
Sung Won Chung, Hye-Sung Moon, Hyunjae Shin, Hyein Han, Sehoon Park, Heejin Cho, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Sung-Ho Won, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Dong Ki Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Yoon Jun Kim
BACKGROUND AIMS: No medication has been found to reduce the liver-related events. We evaluated the effect of sodium-glucose cotransporter-2 inhibitor (SGLT2i) on liver-related outcomes. APPROACH RESULTS: Single nucleotide polymorphisms (SNPs) associated with SGLT2 inhibition were identified, and a genetic risk score (GRS) was computed using the UK Biobank (UKB) data (n=337,138). Two-sample Mendelian randomization (MR) was conducted using the FinnGen (n=218,792) database and UKB data...
March 11, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38466464/hospital-level-care-at-home-for-patients-with-cirrhosis
#17
JOURNAL ARTICLE
Olivia Kahn-Boesel, Henry Mitchell, Lucinda Li, Ennie Zhu, Areej El-Jawahri, David Levine, Nneka N Ufere
BACKGROUND: Patients with cirrhosis have a 30-day readmission rate of over 30%. Novel care delivery models are needed to reduce healthcare costs and utilization associated with cirrhosis care. One such model is Home Hospital (HH), which provides inpatient-level care at home. Limited evidence currently exists supporting HH for cirrhosis patients. AIMS: The aims of this study were to characterize patients with cirrhosis who received hospital-level care at home in a two-site clinical trial and to describe the care they received...
March 11, 2024: Digestive Diseases and Sciences
https://read.qxmd.com/read/38466273/cost-effectiveness-of-strategies-for-treatment-timing-for-perinatally-acquired-hepatitis-c-virus
#18
JOURNAL ARTICLE
Megan Rose Curtis, Rachel L Epstein, Pamela Pei, Benjamin P Linas, Andrea L Ciaranello
IMPORTANCE: Prevalence of chronic hepatitis C virus (HCV) infection among pregnant people is increasing in the US. HCV is transmitted vertically in 7% to 8% of births. Direct-acting antiviral (DAA) therapy was recently approved for children with HCV who are 3 years or older. The clinical and economic impacts of early DAA therapy for young children with HCV, compared with treating at older ages, are unknown. OBJECTIVE: To develop a state-transition model to project clinical and economic outcomes for children with perinatally acquired HCV to investigate the cost-effectiveness of treating at various ages...
March 11, 2024: JAMA Pediatrics
https://read.qxmd.com/read/38466197/immunogenicity-of-covid-19-vaccines-in-patients-with-cirrhosis-a-meta-analysis
#19
JOURNAL ARTICLE
Lichen Ouyang, Gang Lei, Yeli Gong
The immunogenicity of COVID-19 vaccines in patients with liver cirrhosis remains largely unknown. The purpose of this meta-analysis was to investigate the immunogenicity of COVID-19 vaccines in patients with cirrhosis and compare the humoral and cellular immune responses following complete COVID-19 vaccination between cirrhosis patients and healthy controls. A systematic literature search was conducted in PubMed, EMBASE, and Web of Science from 1 January 2020 to 22 August 2023. Sixteen studies with 2127 cirrhosis patients were included...
December 31, 2024: Human Vaccines & Immunotherapeutics
https://read.qxmd.com/read/38460060/expert-consensus-on-the-diagnosis-and-treatment-of-end-stage-liver-disease-complicated-by-infections
#20
EDITORIAL
Tao Chen, Guang Chen, Guiqiang Wang, Sombat Treeprasertsuk, Cosmas Rinaldi Adithya Lesmana, Han-Chieh Lin, Mamun Al-Mahtab, Yogesh K Chawla, Soek-Siam Tan, Jia-Horng Kao, Man-Fung Yuen, Guan-Huei Lee, Diana Alcantara-Payawal, Nobuaki Nakayama, Zaigham Abbas, Wasim Jafri, Dong-Joon Kim, Ashok Choudhury, Rakhi Mahiwall, Jinlin Hou, Saeed Hamid, Jidong Jia, J S Bajaj, Fusheng Wang, Shiv K Sarin, Qin Ning
End-stage liver disease (ESLD) is a life-threatening clinical syndrome and when complicated with infection the mortality is markedly increased. In patients with ESLD, bacterial or fungal infection can induce or aggravate the occurrence or progression of liver decompensation. Consequently, infections are among the most common complications of disease deterioration. There is an overwhelming need for standardized protocols for early diagnosis and appropriate management for patients with ESLD complicated by infections...
March 9, 2024: Hepatology International
keyword
keyword
72152
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.